Clinical trials: Overall Survival
Tumor Response Rate, Overall Survival
TILA-TACE in Treatment of Hepatocellular Carcinoma
To validate the tumor response rate: in the previous study, the investigators showed that TILA-TACE achieved 100% tumor response rate.
- Trial name
- NCT03910140
- Testing
- TILA-TACE treatment
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Event-free Survival, Overall Survival
Transcatheter Intra-arterial Limb Infusion of Cisplatin for Extremity Osteosarcoma
Although there seems to be no benefit from improving the histologic response rate or long-term survival of intra-arterial infusion of cisplatin for localized osteosarcoma of extremities with IOR/OS-3, IOR/OS-5, and COSS 86…
- Conditions
- Event-free Survival, Overall Survival, Local-recurrence Free Survival, Pathological Response
- Trial name
- NCT03909776
- Testing
- Cisplatin
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Peking University People's Hospital
Stomach Neoplasms
Influence of Positive Margins on Tumour Recurrence and Overall Survival After Gastrectomy for Gastric Cancer
Incidence of positive surgical margins after curative gastrectomy ranges from 1% to 20%. It has been suggested that positive surgical margins is an adverse prognosis factor, with a higher local recurrence and worse overall…
- Trial name
- NCT04439812
- Testing
- Observation
- Volunteers
- 267 people
- Sponsor
- Hospital Universitario Ramon y Cajal
Progression-free Survival, Overall Survival
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma
Advanced soft tissue sarcoma patients who have previously recieved anthracyclines might still benefit from doxorubicin, ifosfamide and dacarbazine.
- Conditions
- Progression-free Survival, Overall Survival, Toxicity
- Trial name
- PDVPSTS (NCT03342300)
- Testing
- pegylated liposomal doxorubicin, pirarubicin
- Where
- China
- Sponsor
- Peking University People's Hospital
Squamous Cell Carcinoma of the Head and Neck
SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
This is a retrospective international, multi-center, non-interventional cohort study based on use of data derived from established medical records and secondary analysis of archival tumor samples.
- Trial name
- SUPREME-HN (NCT02543476)
- Where
- 18 sites in United States, Germany and 5 more
- Volunteers
- 412 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Influence of the Use of the Diabetic Drug Metformin on the Overall Survival and Treatment-related Toxicity in Advanced Stage Non-small Cell Lung Cancer Patients.
There are preliminary data suggesting that patients suffering from non-insulin-dependent diabetes mellitus, treated with metformin, have improved local tumor control.
- Trial name
- Metformin (NCT02109549)
- Where
- 3 sites in Netherlands
- Volunteers
- 70 people
- Sponsor
- Maastricht Radiation Oncology
Breast Cancer
Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer
This study will examine the relationship of a protein called pAKT to survival of breast cancer patients with one or more positive axillary lymph nodes.
- Trial name
- NCT00965276
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- National Cancer Institute (NCI)
Liposarcoma of Soft Tissue, Surgical Procedure, Unspecified
Status of Surgical Resection and Histologic Subtype as Predictors of Local Recurrence in Retroperitoneal Liposarcoma
Soft tissue sarcomas are rare malignant tumors. Liposarcoma constitute the most frequent histological subtype of retroperitoneal sarcoma. The prognosis of soft tissue sarcomas depend on clinical and histologic characteristics.
- Trial name
- NCT05428579
- Testing
- Retroperitoneal Liposarcoma resection
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo General Hospital